A synthetic heptapeptide analogue of ACTH 4-10 with pronounced neuroprotective, nootropic, and neurotrophic properties developed for clinical use in Russia.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Semax is a synthetic heptapeptide derived from the amino acid sequence corresponding to positions 4 through 10 of adrenocorticotropic hormone (ACTH), a pituitary peptide with wide-ranging effects on stress response, cortisol regulation, and — notably for Semax’s development — cognitive and neurological function. The ACTH(4-10) fragment had been known since at least the 1970s to exert cognitive effects independent of the adrenocortical axis, meaning it could enhance memory and attention without triggering the cortisol-mediated stress response associated with the full ACTH molecule. This fragment became the starting point for Semax.
The development of Semax was carried out over roughly two decades at the Institute of Molecular Genetics of the Russian Academy of Sciences, with significant contributions from Vladimir Myasoedov and colleagues who recognized that ACTH(4-10)’s rapid in vivo degradation was the primary obstacle to therapeutic application. The solution was chemical modification: by adding a Pro-Gly-Pro tripeptide sequence to the C-terminus of the ACTH(4-10) core, researchers created a compound with dramatically improved metabolic stability. Peptidase enzymes that rapidly cleave the original sequence encounter the Pro-Gly-Pro extension, which is substantially more resistant to degradation — and crucially, the Pro-Gly-Pro addition appears to enhance bioactivity rather than simply serve as a metabolic shield.
The resulting heptapeptide, with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (where the first four residues correspond to ACTH(4-7) and the last three to the stabilizing Pro-Gly-Pro tail), has a molecular weight of approximately 813 daltons. This size places it comfortably within the range for effective intranasal delivery — the primary route used in clinical application and most human research — allowing direct CNS access via olfactory and trigeminal nerve pathways.
Semax was registered as a pharmaceutical drug in Russia in 1994 and has since accumulated an extensive clinical use record for neurological applications. Its approved indications in Russia and several other post-Soviet countries include treatment of ischemic stroke in the acute phase, recovery from transient ischemic attacks, neurological manifestations of atherosclerosis, optic nerve diseases, and cognitive impairment. This clinical registration provides an unusual depth of human safety data for a compound that most researchers in Western countries would classify as a research peptide.
The mechanistic sophistication of Semax — acting through BDNF and NGF pathways, influencing gene expression profiles across dozens of neuroplasticity-related genes, and modulating dopaminergic function — has made it a subject of sustained scientific interest for applications ranging from acute neuroprotection after stroke to enhancement of cognitive performance in healthy subjects. Its dual profile as a neuroprotective and neuroenhancing agent places it at an interesting intersection of therapeutic and research applications.
The most thoroughly characterized mechanism of Semax action involves its ability to rapidly and substantially increase the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in neural tissue. These two members of the neurotrophin family signal through distinct but related receptor tyrosine kinases — BDNF primarily through TrkB, NGF primarily through TrkA — and converge on shared intracellular cascades including the MAPK/ERK pathway (supporting synaptic plasticity, LTP, and gene transcription related to learning) and the PI3K/Akt pathway (supporting neuronal survival, anti-apoptotic signaling, and metabolic support).
Semax-induced BDNF elevation has been documented in multiple brain regions, with the hippocampus and prefrontal cortex showing particularly robust responses. The hippocampus is the primary site of memory consolidation and adult neurogenesis; elevated BDNF in this region facilitates long-term potentiation, supports newly generated neurons in the dentate gyrus, and enhances the structural plasticity of synaptic connections. The prefrontal cortex is the primary site of working memory, executive function, and top-down attentional control; BDNF’s role in maintaining prefrontal dendritic arbor complexity and synaptic density directly supports these cognitive functions. The temporal profile of Semax-induced BDNF elevation — rising within hours of administration and remaining elevated for days in some studies — is consistent with the time course of cognitive effects observed in human research.
Semax’s effects on the dopamine system represent a second major mechanistic strand with direct cognitive relevance. Dopamine signaling in the prefrontal cortex follows an inverted-U dose-response relationship with respect to cognitive performance: too little dopamine tone impairs working memory and attention, too much produces the same result, and the optimal narrow range supports peak prefrontal function. Semax administration has been found to shift dopamine metabolism in the prefrontal cortex toward this optimal range in animal models of stress-induced cognitive impairment (where prefrontal dopamine is typically depleted) without producing the excessive dopamine release associated with stimulant drugs.
In the striatum — particularly the dorsal striatum involved in procedural learning and habit formation, and the ventral striatum (nucleus accumbens) involved in reward and motivation — Semax also modulates dopamine metabolism, with patterns consistent with facilitation of striatal-dependent learning. This bimodal effect on corticostriatal dopamine circuitry provides a mechanistic framework for Semax’s observed effects on both the prefrontal cognitive operations most sensitive to dopamine tone (working memory, sustained attention) and the striatum-dependent procedural and associative learning processes. Importantly, Semax’s dopaminergic effects appear to be modulatory rather than direct agonism at dopamine receptors, which may explain the absence of the tolerance, sensitization, and addiction potential associated with direct dopaminergic stimulants.
Ischemic stroke produces neuronal death through multiple converging mechanisms, of which two of the most important are excitotoxicity (excessive glutamate-mediated NMDA receptor activation leading to calcium overload and necrotic cell death) and apoptotic cascades triggered by metabolic crisis in neurons at the ischemic penumbra — tissue that is damaged but potentially salvageable if perfusion is restored and pro-survival signals are provided. Semax’s ability to upregulate BDNF and NGF directly addresses the apoptotic component: both neurotrophins activate PI3K/Akt-mediated anti-apoptotic cascades and promote the expression of BCL-2 family proteins that prevent mitochondrial permeabilization and caspase activation.
Beyond neurotrophin effects, microarray studies of gene expression following Semax administration in ischemia models have documented upregulation of immediate-early genes including c-Fos, c-Jun, and Egr1 (transcription factors involved in neuroplasticity and stress responses), as well as genes encoding anti-oxidant enzymes, heat-shock proteins, and components of the unfolded protein response — all protective against the metabolic stress of ischemia. The breadth of gene expression changes documented in these studies (more than 24 genes with statistically significant alterations) suggests that Semax does not act through a single molecular mechanism but engages the brain’s endogenous neuroprotective machinery across multiple parallel pathways, a systems pharmacology characteristic that may partly explain its sustained clinical use in stroke recovery over three decades.
The most extensive human evidence for Semax’s efficacy involves its use in acute ischemic stroke, where it has been employed in Russian clinical practice since its 1994 registration. The pivotal Russian clinical trials enrolled patients with acute hemispheric ischemic stroke, administering Semax intranasally at doses of 12-18 mcg/kg/day (roughly 1,000-1,500 mcg/day for an average adult) starting within 24 hours of stroke onset and continuing for 5-10 days. Primary outcomes assessed included neurological deficit scores (using Russian-language adaptations of standard neurological assessment tools), functional independence measures, and in some studies, computed tomography measures of infarct volume.
Results across these trials demonstrated statistically significant reductions in neurological deficit severity in the Semax group compared to control, with the most pronounced differences appearing at 10-day and 30-day assessments — consistent with Semax supporting penumbral neuron survival and recovery rather than simply producing acute symptomatic improvement. A subset of studies found that Semax-treated patients showed reduced infarct volume on follow-up imaging compared to controls, which would represent direct neuroprotection rather than functional compensation. Mortality data from the available trials suggest a trend toward reduced early post-stroke mortality in Semax-treated groups, though individual trials were generally not powered to demonstrate this endpoint with statistical confidence. The accumulated clinical experience over 30+ years in Russian stroke units, while not constituting evidence by Western regulatory standards, represents a remarkable depth of real-world application data.
A series of Russian clinical studies examined Semax’s effects on cognitive performance in populations ranging from healthy volunteers to patients with mild cognitive impairment to children with attention-deficit disorders. In healthy volunteers, acute intranasal Semax administration (typically 400-600 mcg, single dose) produced measurable improvements in attention as assessed by continuous performance tests, with reaction time and error rate both improving compared to placebo in blinded studies. Short-term memory consolidation — tested by recall of word lists or visual sequences at delays of 20-30 minutes — also showed improvement following Semax in several trials.
In a clinical study of patients with chronic cerebrovascular insufficiency (a condition characterized by diffuse small-vessel disease and mild cognitive impairment), 10-day courses of intranasal Semax produced significant improvements in memory test scores, attention measures, and overall cognitive efficiency compared to controls treated with standard pharmacological management. Patient-reported quality of life measures, including assessments of daily functional capacity and subjective cognitive complaints, also showed significant improvements in the Semax group. These findings are clinically meaningful because the cognitive domains most affected — attention and short-term memory — are precisely those most dependent on BDNF-supported hippocampal and prefrontal function, consistent with the mechanistic data.
One of the more clinically distinctive applications supported by published research is Semax’s use in optic nerve pathology. Two conditions have been most studied: primary open-angle glaucoma (POAG), where retinal ganglion cell death and optic nerve fiber loss produce progressive visual field defects, and optic nerve atrophy from various causes including anterior ischemic optic neuropathy and trauma-related injury.
In POAG, Semax has been studied as an adjunct to standard intraocular pressure-lowering therapy. A clinical trial demonstrated that adding intranasal Semax to standard IOP-lowering treatment produced significantly better preservation of visual field and retinal nerve fiber layer thickness over a 12-month follow-up period compared to IOP-lowering therapy alone, suggesting direct neuroprotection of retinal ganglion cells independent of pressure effects. The mechanistic basis is plausible: retinal ganglion cells express TrkB receptors, are dependent on BDNF for survival, and undergo apoptotic death in glaucoma via pathways that BDNF signaling directly counteracts. In optic nerve atrophy studies, Semax treatment was associated with improved visual acuity and electrophysiological measures of optic nerve conduction (visual evoked potential latency and amplitude) in treated subjects versus controls. These findings represent a unique clinical niche for Semax not shared by most other nootropic or neuroprotective compounds.
The mechanistic understanding of Semax’s neuroprotective effects has been substantially advanced by studies in experimental ischemia models, where the molecular events following Semax administration can be examined with a resolution not possible in clinical studies. In the middle cerebral artery occlusion (MCAO) rat model — the most widely used preclinical stroke model — Semax administered intranasally at doses equivalent to those used in human trials produced significant reductions in infarct volume (typically 30-50% smaller than vehicle controls), substantially improved neurological deficit scores, and measurable attenuation of neuroinflammatory markers including IL-1beta, TNF-alpha, and activated microglial density in the peri-infarct zone.
Mechanistic analyses in these ischemia models have revealed a complex cascade initiated by Semax: within hours of administration, BDNF mRNA increases in perilesional cortex; this is followed by upregulation of TrkB protein and downstream ERK phosphorylation; anti-apoptotic BCL-2 expression increases while pro-apoptotic BAX decreases in neurons at the ischemic margin. Concurrently, inflammatory signaling is attenuated through suppression of NF-kB activation in microglia and reduction of pro-inflammatory cytokine production. The timing of these changes — preceding the window of maximal penumbral neuron death — is consistent with an active neuroprotective mechanism rather than passive recovery. These mechanistic insights have been used to design the administration timing in clinical stroke protocols, with early post-onset administration being critical for maximum neuroprotective effect.
Perhaps the most scientifically fascinating data on Semax’s mechanism comes from transcriptomic studies that have examined its effects on CNS gene expression at a genome-wide level. Using microarray and RNA sequencing approaches in rat cortex and hippocampus following intranasal or subcutaneous Semax administration, researchers have documented statistically significant changes in the expression of more than 24 genes, with effects spanning multiple functional categories relevant to brain health and cognitive function.
Upregulated genes include not only BDNF and NGF but also NT-3 (neurotrophin-3, the ligand for TrkC with specific roles in cerebellar function and peripheral nerve maintenance), VEGF (vascular endothelial growth factor, critical for cerebrovascular health and angiogenesis in tissue recovery), and several immediate-early genes encoding transcription factors that amplify and extend the neuroplasticity response. Downregulated genes include those encoding pro-inflammatory cytokines and their receptors, components of oxidative stress pathways, and mediators of excitotoxic cell death. The breadth and coherence of this transcriptomic response — with changes forming a biologically coherent pro-plasticity, anti-inflammatory, anti-apoptotic signature — suggests that Semax acts at a regulatory level that orchestrates multiple downstream pathways rather than simply agonizing or antagonizing a specific receptor type.
The most clearly established dosing for Semax comes from its Russian clinical use, where the standard formulations are 0.1% (1 mg/mL) and 1% (10 mg/mL) intranasal solutions. The approved clinical dosing for stroke treatment is 12-18 mcg/kg/day, which for a 70-80 kg adult corresponds to approximately 840-1,440 mcg/day, typically divided into 3-4 administrations. Lower doses of 200-600 mcg/day have been used in studies of cognitive enhancement in healthy subjects and in mild cognitive impairment, where the neurotrophin-stimulating effects rather than acute neuroprotection are the target. Animal model research uses doses of approximately 25-100 mcg/kg, which translates via human equivalent dose calculation to roughly 4-16 mcg/kg for human research — consistent with the clinical dosing range in use. The peptide dosing calculator provides weight-based dose calculations for research planning.
Intranasal administration is overwhelmingly the most studied and clinically validated route for Semax, and there are compelling mechanistic reasons for preferring this route beyond mere convenience. The olfactory nerve, which traverses the cribriform plate, provides a direct anatomical pathway from nasal mucosa to the brain, and both transcellular and paracellular transport of peptides along this pathway have been demonstrated. Trigeminal nerve pathways provide additional CNS delivery routes. These pathways are collectively responsible for the higher CNS bioavailability of intranasally administered peptides compared to the bioavailability predicted by systemic plasma levels alone. For Semax specifically, studies using radiolabeled compound have documented significant brain parenchymal concentration within 30 minutes of intranasal dosing, with regional distribution that includes olfactory bulb, hippocampus, and cortex.
Technique matters for intranasal delivery: both nostrils should be used alternately (or simultaneously, as used in some clinical protocols), with the head slightly tilted forward rather than back to prevent drainage into the throat, and gentle sniffing after delivery helps distribute the solution across the olfactory mucosa rather than concentrating it anteriorly near the nasal vestibule. Typical research-grade nasal spray pumps deliver 50-100 mcL per actuation, so solution concentration and pump calibration determine per-actuation dose.
Research-grade Semax is typically supplied as lyophilized powder requiring reconstitution with bacteriostatic water or sterile saline. Target concentration depends on the desired dose per nasal spray actuation — for a standard 100 mcL/actuation pump delivering 200 mcg per spray, a concentration of 2 mg/mL (0.2%) is appropriate. Semax is somewhat more susceptible to oxidative degradation than some other research peptides due to its methionine residue (Met at position 1); antioxidant additives or minimization of air exposure during handling help maintain stability. Reconstituted solutions stored at 2-8°C in amber vials are generally considered stable for 3-4 weeks. Lyophilized powder stored at -20°C with protection from moisture maintains potency for significantly longer periods, with stability studies supporting at least 24-month shelf life under optimal conditions. For detailed reconstitution calculations, see the Peptides Helper calculator.
Russian clinical practice has used both short-course acute treatment (5-14 days for stroke) and longer maintenance courses (up to 30 days with rest periods) for chronic neurological conditions. For nootropic applications, research protocols have varied widely — from single acute doses in healthy volunteer studies to daily administration for 10-14 days in cognitive impairment studies. The available data do not provide clear evidence for or against longer continuous use; the potential concern with sustained high-dose neurotrophin stimulation (theoretical risk of receptor downregulation or altered synaptic development in young individuals) has not been systematically studied for Semax specifically, though BDNF receptor systems generally show robust long-term responsiveness without clear downregulation in published research. Researchers working with Semax protocols may find relevant design considerations in the AI coach and the peptide database.
Semax’s three decades of clinical use in Russia, including large retrospective registry data and prospective trials, provide a substantially more developed safety picture than is available for most research peptides. At the doses used clinically (12-18 mcg/kg/day intranasally for acute applications; lower doses for cognitive indications), Semax has shown a favorable safety profile. The most commonly reported adverse effects are local nasal effects from intranasal delivery — mild mucosal irritation, rhinorrhea, and occasionally transient mild discomfort — which are related to the delivery route rather than the compound’s pharmacological activity. Systemic adverse effects have been uncommon and generally mild in clinical reports: occasional headache, dizziness, and short-lived increased energy that some subjects find stimulating and others mildly uncomfortable. No significant organ toxicity (cardiovascular, hepatic, renal, or hematological) has been identified in clinical monitoring data.
While Semax is not a stimulant in the pharmacological sense — it does not directly release catecholamines or block their reuptake — its dopaminergic modulating effects and the subjective energy and mental activation many users report warrant attention in the safety context. Reports from research subjects and clinical patients describe increased alertness, mental energy, and reduced fatigue that, while generally experienced as beneficial, can manifest as difficulty sleeping if doses are taken late in the day. Some individuals report mild anxiety or overstimulation, particularly at higher doses, which may reflect excessive BDNF-driven neuroplasticity or dopamine modulation in individuals with pre-existing anxiety or vulnerability to psychostimulant-like effects. Standard research protocol guidance therefore recommends morning or early-afternoon administration only, and careful titration starting at the lower end of the dose range.
Semax’s primary mechanism — upregulation of neurotrophins including BDNF — raises theoretical considerations in specific populations. BDNF has well-documented roles in synaptic plasticity that includes both potentiation and pruning of synaptic connections; in developing brains (children and adolescents), the consequences of exogenous neurotrophin manipulation are less predictable than in adults. Semax’s use in pediatric ADHD and learning disability research (which exists in Russian literature) is intriguing but should be viewed with caution given these theoretical concerns. Individuals with a history of seizure disorders should be aware that BDNF is pro-convulsant in some experimental contexts, though Semax has not been associated with increased seizure frequency in clinical use. Drug interactions have not been systematically studied; theoretical interactions with MAO inhibitors and dopaminergic agents are possible given Semax’s dopamine-modulating effects. As with Selank, the Western research community should be aware that the primary literature base is Russian, with associated methodological heterogeneity that limits cross-study comparison. Consult the peptide database for the latest published safety literature.
Semax is both, and the distinction between these categories is less clear at the mechanistic level than it might appear. Its approved clinical uses in Russia are primarily neuroprotective — stroke recovery, chronic cerebrovascular insufficiency, optic nerve protection — but the same BDNF/NGF-mediated mechanisms that protect neurons under pathological stress also enhance synaptic plasticity and cognitive function in healthy brains. Research in healthy volunteers has demonstrated nootropic effects (improved attention, memory, and processing speed) that are not simply a consequence of treating subclinical pathology. A useful framing is that Semax activates and amplifies the brain’s endogenous neuroplasticity mechanisms, which produces neuroprotection when those mechanisms are needed for cell survival and cognitive enhancement when the brain is healthy but operating below its adaptive potential.
Conventional ADHD medications — methylphenidate, amphetamine salts — work primarily by increasing synaptic dopamine and norepinephrine availability in the prefrontal cortex through reuptake inhibition or enhanced release. They produce immediate, robust improvements in attention and impulse control at the cost of cardiovascular stimulation, appetite suppression, sleep disruption, and significant abuse potential. Semax’s dopaminergic effects are modulatory rather than direct, producing more subtle and gradual improvements in prefrontal dopamine tone with a markedly more favorable side effect profile and no identified abuse potential. The tradeoff is lower magnitude of acute effect — Semax will not produce the dramatic attentional improvements some ADHD patients experience with stimulants. Russian research in children with attention difficulties has reported meaningful improvements in attention and school performance with Semax, but direct head-to-head comparison data with standard ADHD medications is not available.
The neurobiological overlap between depression and the conditions Semax is most studied for — BDNF deficiency, hippocampal atrophy, prefrontal dopamine deficiency, and impaired synaptic plasticity — is substantial. The “neurotrophic hypothesis of depression” specifically implicates reduced BDNF as a central feature of depressive pathology, and all effective antidepressants (regardless of mechanism) have been found to increase BDNF in the hippocampus with chronic administration. Semax’s direct, rapid BDNF-elevating effect is therefore mechanistically convergent with antidepressant action. However, there are no published clinical trials of Semax specifically in major depressive disorder meeting contemporary standards, and it would be premature to conclude from mechanism alone that it functions as an antidepressant. Reports from research subjects suggest mood-brightening effects, but controlled evidence is lacking. This is an area where future research would be scientifically interesting.
Like virtually all peptides, Semax is rapidly degraded in the gastrointestinal tract by proteolytic enzymes — the same enzymes that digest dietary protein will efficiently cleave the peptide bond chain of Semax before meaningful absorption can occur. Even if some absorption occurred, the portal circulation would deliver the compound directly to the liver, where extensive first-pass peptide metabolism would further reduce systemic availability. The intranasal route bypasses both of these obstacles: the nasal mucosa has significantly lower peptidase activity than the GI tract, and olfactory/trigeminal transport pathways deliver drug directly to the CNS without requiring systemic circulation. Subcutaneous injection is also effective (and is used in research settings) but lacks the direct CNS delivery advantage of the intranasal route and requires injection equipment and technique.
Clinical protocols in Russian practice have used 5-30 day courses depending on indication, and published research studies have used similar durations. The effects are not permanent in the sense of producing irreversible changes, but some outcomes may be more durable than the treatment course itself: neuroplasticity-enhancing compounds that support synaptic consolidation can produce lasting improvements in learned skills or consolidated memories even after the acute neurochemical effect wanes. Neuroprotective effects in stroke — protecting neurons from death during the acute ischemic event — are by definition permanent if they succeed. For cognitive enhancement in healthy subjects, the effects appear to persist for days to weeks after a treatment course ends, with individual variability in the rate of return to baseline.
Semax’s pharmacological profile is distinct from most commonly co-administered nootropics (racetams, choline supplements, adaptogens), and there are no identified pharmacokinetic or pharmacodynamic interactions between Semax and these compound classes in the published literature. Selank and Semax are sometimes discussed together in the Russian nootropic research literature, and the theoretical complementarity of Selank’s anxiolytic-GABA mechanism with Semax’s neurotrophin-dopamine mechanism has led to some investigator interest in combination use. Published data on this specific combination are limited. The primary safety consideration for any Semax combination is the stimulant-like CNS activation effect — adding other compounds that increase alertness or CNS arousal could compound this effect. Consult the AI coach for a review of what the literature says about specific combinations you may be researching.
This is a logical question given Semax’s derivation from ACTH, which is the pituitary hormone that stimulates adrenal cortisol production. However, ACTH’s cortisol-stimulating activity resides primarily in the C-terminal portion of the molecule (ACTH(17-39) is responsible for steroidogenic activity), while the ACTH(4-10) sequence from which Semax is derived specifically lacks steroidogenic activity. Multiple studies have confirmed that Semax administration does not produce measurable changes in plasma cortisol, ACTH, or adrenal hormones at doses used in research and clinical practice. This dissociation from the HPA axis — cognitive effects without stress hormone activation — was one of the key motivations for developing the ACTH(4-10) analog and remains one of Semax’s most pharmacologically significant features.
Published Russian clinical protocols form the primary literature base for Semax dosing and administration, and many are available through PubMed with English abstracts. The Peptides Helper database aggregates research references organized by application and dose range, providing a starting point for protocol design. For interpretation of specific study designs or help navigating the literature for particular research applications, the AI coach can assist with reviewing and contextualizing the available evidence.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.